Triple Drug Combination Targets Prostate Cancer Cells
Author Information
Author(s): Wedel Steffen, Hudak Lukasz, Seibel Jens-Michael, Makarević Jasmina, Juengel Eva, Tsaur Igor, Waaga-Gasser Ana, Haferkamp Axel, Blaheta Roman A
Primary Institution: Goethe-University; Frankfurt am Main; Germany
Hypothesis
Combined interference with VEGFr/EGFr, mTOR and HDAC dependent activation processes might be superior to blocking each pathway separately.
Conclusion
The triple drug combination significantly reduces prostate cancer cell growth and adhesion, suggesting a potential advancement in treatment strategies.
Supporting Evidence
- All drugs reduced tumor cell adhesion, migration, and growth.
- The triple drug combination had a much stronger anti-cancer effect than any single drug.
- Cell cycle regulating proteins were significantly altered by the triple drug treatment.
- Integrin expression patterns were modified by the drug combination.
Takeaway
Using three different medicines together can help fight prostate cancer better than using just one medicine at a time.
Methodology
Prostate cancer cell lines were treated with RAD001, AEE788, and VPA, and various assays were performed to assess cell growth, adhesion, and signaling pathways.
Limitations
The study primarily focuses on in vitro results, which may not fully translate to in vivo effectiveness.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website